Opioid-induced constipation – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) and used off-label. However, many patients turn to over-the-counter (OTC) therapies, keeping drug treatment rates low. As a result, recently approved therapies such as Motegrity and Zelnorm have had difficulty gaining market share. More-established therapies such as Linzess and Movantik continue to secure use in both newly diagnosed and recently treated patients. Persistency and compliance rates are relatively low in this market compared with other indications, highlighting the importance of securing early use.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
- How have Linzess and Motegrity been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of OIC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of OIC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Allergan, Ironwood, Synergy Pharma, Takeda, Mallinckrodt, Alfasigma, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Endo Pharma
Key drugs: Motegrity, Linzess, Trulance, Ibsrela, Relistor, Symproic, Movantik, Amitiza, lubiprostone generic, naloxone, stimulant laxatives, osmotic laxatives, dietary fiber supplements
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
Shubhendu Ghosh, Ph.D., Senior Healthcare Research & Data Analyst, Immune and Inflammation. Dr. Ghosh’s focus is the asthma and urticaria therapy markets. Previously, he was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.